XBiotech Inc. (XBIT) Form 10-Q — May 14, 2026
XBiotech Inc. reported a net loss of $5.5 million for the first quarter of 2026, a significant improvement from the $10.9 million loss recorded in the same period last year. The reduction in losses was primarily driven by lower operating expenses, specifically the absence of a $4 million bonus paid to former CEO John Simard in Q1 2025, which had inflated prior-year R&D and G&A costs. The company maintains a strong balance sheet with $115.5 million in cash and cash equivalents and no debt, having fully repaid a $10 million related-party convertible loan in January 2025.
Key figures
- Total Debt
- 0
- Total Assets
- 139836000
- Cash Position
- 115459000
- Shares Outstanding
- 30487731
- Ga expense q1 2025
- 1931000
- Ga expense q1 2026
- 1068000
- Rd expense q1 2025
- 11619000
- Rd expense q1 2026
- 5206000
- Share based compensation
- 172000
Price after filing
Close on the filing date to close N calendar days later (from $2.50). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.